Veraxa Biotech Holding AG
NASDAQ: VRXA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christoph Antz
- Employees
- 8
- Headquarters
- Zurich, Switzerland
- IPO year
- 2026
- Market cap
- $243.9M
- Website
- https://www.veraxa.com
Loading VRXA…
Loading profile data…Frequently asked questions about VRXA
What does Veraxa Biotech Holding AG (VRXA) do?
Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company, formed via a merger with Voyager Acquisition Corp., focusing on developing next-generation cancer therapies such as antibody-drug conjugates (ADCs) and bispecific T-cell engagers. [64, 65]
Where does VRXA trade?
Veraxa Biotech Holding AG (VRXA) trades on the NASDAQ.
What sector is VRXA in?
Veraxa Biotech Holding AG (VRXA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Veraxa Biotech Holding AG?
Christoph Antz is the chief executive officer of Veraxa Biotech Holding AG (VRXA).
Where is Veraxa Biotech Holding AG headquartered?
Veraxa Biotech Holding AG is headquartered in Switzerland.
Does VRXA pay a dividend?
Veraxa Biotech Holding AG (VRXA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VRXA go public?
Veraxa Biotech Holding AG (VRXA) completed its initial public offering in 2026.